This activation is achieved by proteins
called epigenetic regulators, which work to make specific regions of our genome more or less accessible to transcription.
The drug, lapatinib, activates the suppressor
called FOXO, in HER2 + breast cancer cells, but then FOXO becomes a turncoat molecule, working with an
epigenetic regulator that controls gene expression.